{"id":80667,"date":"2026-05-15T00:00:39","date_gmt":"2026-05-15T00:00:39","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/"},"modified":"2026-05-15T00:00:39","modified_gmt":"2026-05-15T00:00:39","slug":"sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/","title":{"rendered":"SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of &#8216;SNB-101&#8217;"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2980798\/SN_BioScience_Inc_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\">SEONGNAM, South Korea<\/span>, May 15, 2026 \/PRNewswire\/ &#8212; SN\u00a0BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b\/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer agent, in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>This multi-center trial, conducted across sites globally including the United States and Europe, will enroll up to 135 patients. The study is designed in three sequential stages: a Phase 1b dose-escalation phase using a 3+3 design to determine the Maximum Tolerated Dose (MTD) at dose levels of 50\u201370 mg\/m\u00b2, followed by a two-part Phase 2 consisting of Phase 2a and Phase 2b. Phase 2a will conduct dose optimization to identify the optimal therapeutic dose, after which Phase 2b will proceed with dose expansion at the optimized dose to further evaluate clinical activity across a broader patient population. Across Phase 2, key efficacy endpoints including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) will be assessed to generate the clinical evidence necessary to support regulatory review process.<\/p>\n<p>The advancement into Phase 2 is supported by encouraging prior Phase 1 results conducted in Korea, in which SNB-101 demonstrated a favorable safety profile with no Grade 3 or higher diarrhea events, a disease control rate (DCR) of 83.3% in high-dose cohorts, and a mean progression-free survival (PFS) of 6.3 months in SCLC patients. These findings compare favorably with outcomes historically reported for currently available later-line treatment options, including Zepzelca\u00ae and Topotecan.<\/p>\n<p>Based on its Phase 1 results, SNB-101 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for SCLC. Together with Orphan Drug Designation from the FDA and EMA, these designations reflect that SNB-101 has fully established the regulatory framework necessary to pursue accelerated approval.<\/p>\n<p>As a monotherapy, SNB-101 has demonstrated encouraging clinical activity together with a favorable tolerability profile in previously treated SCLC patients. The company believes these findings support the continued clinical development of SNB-101 as a potential treatment option for patients with relapsed SCLC, particularly in later-line settings where tolerability and efficacy remain an important unmet need.<\/p>\n<p>In parallel with the ongoing monotherapy program, SN BioScience is actively expanding the development of SNB-101 into combination strategies with immunotherapy agents (including anti-PD-1, anti-PD-L1, and DLL3-targeted BiTE\u00ae T-cell engager therapies) currently used in standard SCLC treatment. The company has already obtained EMA approval for a clinical study evaluating SNB-101 in combination with one immunotherapy agent and is planning to submit an additional CTA within this year for a separate study involving another immunotherapy combination.<\/p>\n<p>In addition, SN BioScience is pursuing the expansion of SNB-101 into additional solid tumor indications, including gastric and pancreatic cancers, through ongoing collaborations and strategic discussions with global pharmaceutical companies.<\/p>\n<p>\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEONGNAM, South Korea, May 15, 2026 \/PRNewswire\/ &#8212; SN\u00a0BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b\/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer agent, in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). This multi-center trial, [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-80667","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of &#039;SNB-101&#039; - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of &#039;SNB-101&#039;\" \/>\n<meta property=\"og:description\" content=\"SEONGNAM, South Korea, May 15, 2026 \/PRNewswire\/ &#8212; SN\u00a0BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced t\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-15T00:00:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1074\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of &#8216;SNB-101&#8217;\",\"datePublished\":\"2026-05-15T00:00:39+00:00\",\"dateModified\":\"2026-05-15T00:00:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/\"},\"wordCount\":464,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/\",\"name\":\"SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of 'SNB-101' - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-05-15T00:00:39+00:00\",\"dateModified\":\"2026-05-15T00:00:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of &#8216;SNB-101&#8217;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of 'SNB-101' - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/","og_locale":"en_US","og_type":"article","og_title":"SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of 'SNB-101'","og_description":"SEONGNAM, South Korea, May 15, 2026 \/PRNewswire\/ &#8212; SN\u00a0BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced t","og_url":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-05-15T00:00:39+00:00","og_image":[{"width":1074,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/05\/SaigonBiz-Feature-Image.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of &#8216;SNB-101&#8217;","datePublished":"2026-05-15T00:00:39+00:00","dateModified":"2026-05-15T00:00:39+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/"},"wordCount":464,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/","url":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/","name":"SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of 'SNB-101' - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-05-15T00:00:39+00:00","dateModified":"2026-05-15T00:00:39+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/sn-bioscience-doses-first-patient-in-phase-1b-2-clinical-trial-of-snb-101\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"SN BioScience Doses First Patient in Phase 1b\/2 Clinical Trial of &#8216;SNB-101&#8217;"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/80667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=80667"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/80667\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=80667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=80667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=80667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}